Andrew Bishop, MD
Psychiatry · Jackson, MSNPI 1881702710
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 373 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$991
- Neurocrine Biosciences, Inc.$806
- AbbVie$616
- Takeda Pharmaceuticals U.S.A., Inc.$574
- Otsuka America Pharmaceutical, Inc.$435
- Axsome Therapeutics, Inc.$404
- plus $2K from 23 others
Across 11 payments — averaging $1362.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$15K
- AbbVie$482
What the payments were for
- Food & beverage$5,78094%
- Education$3756%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 46 | $991 |
| Neurocrine Biosciences, Inc. | 63 | $806 |
| AbbVie(2 entities) | 47 | $616 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $574 |
| Otsuka America Pharmaceutical, Inc. | 26 | $435 |
| Axsome Therapeutics, Inc. | 22 | $404 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $364 |
| Vanda Pharmaceuticals Inc. | 15 | $328 |
| Johnson & Johnson | 7 | $271 |
| Alkermes, Inc. | 10 | $215 |
| Lundbeck LLC | 14 | $213 |
| Sunovion Pharmaceuticals Inc. | 22 | $197 |
| Eisai Inc. | 7 | $109 |
| Biogen | 1 | $89 |
| Idorsia Pharmaceuticals US Inc | 5 | $80 |
| Supernus Pharmaceuticals, Inc. | 4 | $59 |
| Tris Pharma Inc | 3 | $58 |
| Neuronetics, Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Corium, LLC | 2 | $37 |
| Livanova USA, Inc. | 2 | $35 |
| Kerecis Limited | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $23 |
| Indivior Inc. | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
How this compares
$6,155 in reported general payments places this provider in the 90th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 53 | $400,038 |
| Austedo XrDeutetrabenazine | 24 | $168,514 |
| Abilify MaintenaAripiprazole | 16 | $46,098 |
| Aripiprazole | 455 | $18,995 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 781 | $14,594 |
| Lurasidone Hcl | 85 | $13,867 |
| Quetiapine Fumarate | 485 | $7,836 |
| Asenapine Maleate | 22 | $6,785 |
| Ziprasidone Hcl | 63 | $5,336 |
| Hydroxyzine Hcl | 211 | $5,158 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,043 |
| Alprazolam | 587 | $4,998 |
| Chlorpromazine Hcl | 22 | $4,794 |
| Clonazepam | 502 | $4,316 |
| Trazodone Hcl | 454 | $4,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $806 | $400,03853 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $991 | $168,51424 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $435 | $46,09816 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $574 | $5,04311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Jackson
- Jon JacksonJackson$834K
- John NortonJackson$173K
- Krishan GuptaJackson$26K
- Kristen BevillJackson$12K
- Mark ResterJackson$9K
- Roy ReevesJackson$8K
- Hunter McLendonJackson$5K
- Douglas ByrdJackson$5K
- Marshall BelagaJackson$5K
- Amandeep SinghJackson$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.